Collaborations, contracts and licensing agreements (Details) $ / shares in Units, $ in Thousands					3 Months Ended		6 Months Ended	9 Months Ended	72 Months Ended
	Jan. 06, 2022 USD ($)	Jan. 05, 2022 USD ($)	Jul. 02, 2019 USD ($)	Jan. 01, 2019 USD ($)	Mar. 31, 2026 USD ($) product shares	Mar. 31, 2025 USD ($)	Jun. 30, 2017 USD ($)	Sep. 30, 2025 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2025 shares	Dec. 13, 2021 USD ($) $ / shares shares
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Common shares, shares issued (in shares) | shares					196,947,757					192,531,225
Number of royalty entitlements | product					2
Non Cash Royalty Revenue Related To Sale Of Future Royalties					$ 181	$ 448
Qilu Pharmaceutical Co, LTD.
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Income taxes paid								$ 4,400
Common Shares | Qilu Pharmaceutical Co, LTD.
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Noncontrolling interest, ownership percentage by noncontrolling owners											2.50%
Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty interest, % interest					0.75%
Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty interest, % interest					1.125%
Vaccitech
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Costs related to collaboration					$ 300	300
OMERS
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Gross proceeds from sale of royalty interest. before advisory fees				$ 20,000
Entitlement of royalties to be received			$ 30,000	30,000
Future royalty payments			$ 30,000	$ 30,000
Non Cash Royalty Revenue Related To Sale Of Future Royalties					200	400			$ 26,700
OMERS | Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty interest, % interest			1.00%				1.00%
OMERS | Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty interest, % interest			2.33%				2.33%
Arbutus Biopharma Corp
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty guarantees commitments percentage			100.00%	100.00%
Qilu Pharmaceutical Co, LTD.
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential milestone payments											$ 245,000
Amortization of other deferred charges					100	$ 100
Qilu Pharmaceutical Co, LTD. | Common Shares
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Common shares, shares issued (in shares) | shares											3,579,952
Share price (in USD per share) | $ / shares											$ 4.19
Premium on closing stock price (as a percent)											15.00%
Issuance of common shares pursuant to the Open Market Sale Agreement	$ 15,000
Qilu Pharmaceutical Co, LTD. | One-Time Upfront Cash Payment
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from collaborators		$ 40,000
Qilu Pharmaceutical Co, LTD. | Labor hours
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Deferred revenue recognized					800
ONPATTRO
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty interest sold, annual revenue threshold of highest tier			$ 500,000		$ 500,000		$ 500,000
Barinthus Biotherapeutics plc
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percent of Costs related to Collaboration					50.00%